Health
PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan – Medscape
Sacubitril valsartan (Entresto), deemed ‘the Big E’ by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific…
The PARADISE-MI trial comparing sacubitril/valsartan to ramipril in patients with left ventricular dysfunction after myocardial infarction (MI) and clinical heart failure led off the late-breaking clinical trial session at the American College of Cardiology (ACC) 2021 Scientific Session. Organizers tend to reserve this slot for the biggest newsmakers.
And if the angiotensin neprilysin inhibitor had been associated with a statistically significant reduction of the primary endpoint of cardiovascular…
Continue Reading
